Residents' Association Werdenberg


FDA approves flibanserin for hypoactive sexual desire disorder in postmenopausal women

Other > flibanserin


Sensitivity analysis performed by omitting each trial to search for the sources of heterogeneity of flibanserin 100 mg on SSE in premenopausal women showed that none of the trials could substantially influence the pooled effect.

  • Flibanserin should be discontinued if no benefit is observed after several weeks.
  • The medication's influence on mental health conditions is still being studied.
  • Flibanserin was recognized as a breakthrough therapy for female sexual desire issues.
  • Its use is guided by strict medical protocols due to safety concerns.
  • Women are encouraged to report any adverse effects during treatment.
  • Continued research aims to improve treatment options for female sexual health.
  • Flibanserin is one of a few FDA-approved drugs for Female Sexual Desire Disorder.
  • Clinical improvements may include increased frequency of satisfying sexual events.
  • The drug's use should be combined with counseling when appropriate.

Forest plot highlighting the change from baseline in (A) SSE in premenopausal women, Flibanserin 100 mg vs Placebo; (B) SSE in premenopausal women, Flibanserin 50 mg vs Placebo; (C) SSE in postmenopausal women, Flibanserin 100 mg vs Placebo; (D) e-Diary sexual desire score in premenopausal women, Flibanserin 100 mg vs Placebo; (E) e-Diary sexual desire score in premenopausal women, Flibanserin 50 mg vs Placebo.

I feel stressed due to my low desire

Such a beneficial effect was not observed with flibanserin 50 mg dose in premenopausal women (MD 0.74, 95% CI [−0.52, 1.99], P = .25, I2 = 80% [high heterogeneity]) (Fig. FSDS-R item 13 and total scores Flibanserin 100 mg also outperformed placebo in reducing FSDS-R Item 13 scores in both premenopausal (MD −0.30, 95% CI [−0.31, −0.29], P < .00001, I2 = 0% [not important heterogeneity]) (Fig. 4A), and postmenopausal women (MD −0.20, 95% CI [−0.39, −0.01], P = .04, I2 super p force uk = 0% [not important heterogeneity]) (Fig. The efficacy of flibanserin 50 mg in reducing FSDS-R Item 13 scores in premenopausal women was similar to placebo (MD −0.10, 95% CI [−0.29, 0.09], P = .31, I2 = 0% [not important heterogeneity]) (Fig. Forest plot highlighting the change from baseline in (A) FSDS-R Item 13 score in premenopausal women, Flibanserin 100 mg vs Placebo; (B) FSDS-R Item 13 score in premenopausal women, Flibanserin 50 mg vs Placebo; (C) FSDS-R Item 13 score in postmenopausal women, Flibanserin 100 mg vs Placebo; (D) FSDS-R total score in premenopausal women, Flibanserin 100 mg vs Placebo; (E) FSDS-R total score in premenopausal women, Flibanserin 50 mg vs Placebo; (F) FSDS-R total score in postmenopausal women, Flibanserin 100 mg vs Placebo.

Missed Dose Instructions

In premenopausal women, flibanserin was superior to placebo in reducing FSDS-R total scores at both 100 mg (MD −3.30, 95% CI [−3.37, −3.23], P < .00001, I2 = 0% [not important heterogeneity]) (Fig. A similar benefit of flibanserin 100 mg over placebo was also observed in postmenopausal women (MD −2.42, 95% CI [−3.68, −1.16], P = .0002, I2 = 0% [not important heterogeneity]) (Fig. Postmenopausal women treated with flibanserin 100 mg showed a similar change in PGI-I score compared to those treated with placebo (MD −0.15, 95% CI [−0.44, 0.14], P = .32, I2 = 56% [moderate heterogeneity]) (Fig. In premenopausal women, a higher number of subjects achieved improvements in the PGI-I score in the flibanserin 100 mg arm (OR 1.93, 95% CI [1.58, 2.36], P < .00001, I2 = 32% [mild heterogeneity]) (Fig. Forest plot highlighting the (A) Change from baseline in PGI-I score in postmenopausal women, Flibanserin 100 mg vs Placebo; (B) Proportions of premenopausal women with improvement in PGI-I score, Flibanserin 100 mg vs Placebo; (C) Proportions of premenopausal women with improvement in PGI-I score, Flibanserin 50 mg vs Placebo; (D) Proportions of premenopausal women responded positively at PBE, Flibanserin 100 mg vs Placebo; (E) Proportions of premenopausal women responded positively at PBE, Flibanserin 50 mg vs Placebo; (F) Proportions of postmenopausal women responded positively at PBE, Flibanserin 100 mg vs Placebo. 3.5.2.

  • Flibanserin was developed by Boehringer Ingelheim, later licensed to Sprout Pharmaceuticals.
  • It is considered a "female Viagra," though its mechanism differs from male erectile drugs.
  • The medication is part of the growing field of female sexual dysfunction treatment.
  • Most clinical trials showed a modest increase in satisfying sexual events.
  • Flibanserin should be taken consistently for best results.
  • It is not recommended for women who are pregnant or breastfeeding.
  • Common adverse reactions include dry mouth and insomnia.
  • The drug was approved after extensive clinical trials involving thousands of women.
  • Long-term safety data is still being collected.

eDiary sexual desire score Flibanserin 100 mg outperformed placebo in improving sexual desire score measured using eDiary (MD 1.71, 95% CI [0.43, 2.98], P = .009, I2 = 0% [not important heterogeneity], moderate certainty of evidence) (Fig. Such benefit was not observed with flibanserin 50 mg over placebo (MD 0.67, 95% CI [−0.71, 2.05], P = .34, I2 = 0% [not important heterogeneity]) (Fig.

Issue Description
Efficacy Debate Some experts question the clinical significance of benefits
Side Effect Concerns Risks of hypotension, syncope, and severe allergic reactions
Marketing & Approval Controversies Criticism over FDA approval process and marketing practices
Post-Marketing Surveillance Ongoing monitoring for rare adverse events

Effect of flibanserin on secondary efficacy outcomes Compared to placebo, greater increments in FSFI desire domain scores were observed in premenopausal women with flibanserin 100 mg (MD 0.30, 95% CI [0.29, 0.31], P < .00001, I2 = 0% [not important heterogeneity]) (Fig. A similar benefit was observed with flibanserin 100 mg in postmenopausal women (MD 0.25, 95% CI [0.06, 0.44], P = .01, I2 = 0% [not important heterogeneity]) (Fig. Forest plot highlighting the change from baseline in (A) FSFI-d score in premenopausal women, Flibanserin 100 mg vs Placebo; (B) FSFI-d score in premenopausal women, Flibanserin 50 mg vs Placebo; (C) FSFI-d score in postmenopausal women, Flibanserin 100 mg vs Placebo; (D) FSFI total score in premenopausal women, Flibanserin 100 mg vs Placebo; (E) FSFI total score in premenopausal women, Flibanserin 50 mg vs Placebo; (F) FSFI total score in postmenopausal women, Flibanserin 100 mg vs Placebo. Flibanserin 100 mg was better than placebo in improving FSFI total scores in both premenopausal (MD 2.51, 95% CI [1.47, 3.55], P < .00001, I2 = 90% [high heterogeneity]) (Fig. 3D), and postmenopausal women (MD 1.42, 95% CI [0.56, 2.29], P = .001, I2 = 0% [not important heterogeneity]) (Fig. Such a beneficial effect was not observed with flibanserin 50 mg dose in premenopausal women (MD 0.74, 95% CI [−0.52, 1.99], P = .25, I2 = 80% [high heterogeneity]) (Fig. FSDS-R item 13 and total scores Flibanserin 100 mg also outperformed placebo in reducing FSDS-R Item 13 scores in both premenopausal (MD −0.30, 95% CI [−0.31, −0.29], P < .00001, I2 = 0% [not important heterogeneity]) (Fig.

Product Dosage Quantity + Bonus Price
Cialis Professional40mg60 + 2 Pills262.32€ 249.83€
Kamagra 100 mg100 mg32 Pills121.24€ 115.47€
Kamagra 100 mg100 mg180 + 6 Pills436.79€ 415.99€
Cialis Generic20mg20 Pills54.72€ 52.11€
Kamagra Gold50 mg12 Pills47.30€ 45.05€
Viagra Professional100mg180 + 4 Pills337.30€ 321.24€
Cialis Professional20mg20 Pills78.33€ 74.60€
Super Kamagra160 mg20 + 4 Pills155.35€ 147.95€
Levitra Generic10mg30 + 4 Pills62.39€ 59.42€
Cialis Super Active20mg20 + 4 Pills92.35€ 87.95€
Viagra Generic200mg20 Pills61.69€ 58.75€
Viagra Original100mg48 + 4 Pills207.15€ 197.29€
Kamagra Gold50 mg32 Pills103.06€ 98.15€

4A), and postmenopausal women (MD −0.20, 95% CI [−0.39, −0.01], P = .04, I2 super p force uk = 0% [not important heterogeneity]) (Fig. The efficacy of flibanserin 50 mg in reducing FSDS-R Item 13 scores in premenopausal women was similar to placebo (MD −0.10, 95% CI [−0.29, 0.09], P = .31, I2 = 0% [not important heterogeneity]) (Fig. Forest plot highlighting the change from baseline in (A) FSDS-R Item 13 score in premenopausal women, Flibanserin 100 mg vs Placebo; (B) FSDS-R Item 13 score in premenopausal women, Flibanserin 50 mg vs Placebo; (C) FSDS-R Item 13 score in postmenopausal women, Flibanserin 100 mg vs Placebo; (D) FSDS-R total score in premenopausal women, Flibanserin 100 mg vs Placebo; (E) FSDS-R total score in premenopausal women, Flibanserin 50 mg vs Placebo; (F) FSDS-R total score in postmenopausal women, Flibanserin 100 mg vs Placebo.

  • Flibanserin is classified as a centrally acting serotonergic agent.
  • It is not a testosterone-based therapy, unlike some other treatments.
  • The FDA approval was based on studies showing increased sexual desire in women.
  • The medication can cause sleep disturbances, including somnolence.
  • Flibanserin has a potential for drug interactions with CYP3A4 inhibitors.
  • It is recommended to start treatment at least 4 weeks before expecting improvement.
  • Discontinuation of the drug normally leads to the loss of effects.
  • The drug's efficacy is modest compared to some male sexual dysfunction drugs.
  • Initiation of therapy involves screening for contraindications.

In premenopausal women, flibanserin was superior to placebo in reducing FSDS-R total scores at both 100 mg (MD −3.30, 95% CI [−3.37, −3.23], P < .00001, I2 = 0% [not important heterogeneity]) (Fig. A similar benefit of flibanserin 100 mg over placebo was also observed in postmenopausal women (MD −2.42, 95% CI [−3.68, −1.16], P = .0002, I2 = 0% [not important heterogeneity]) (Fig.

Side Effects of flibanserin

By modulating these monoamines in patients with HSDD, flibanserin improves sexual desire and arousal. In premenopausal women, flibanserin use was associated with 0.69 and 0.32 additional SSE per month at 100 and 50 mg daily doses; the number was 0.37 in postmenopausal women with flibanserin 100 mg. The improvement is not as robust as expected. US FDA report on the approval of flibanserin 100 mg mentioned that, on average, treatment with flibanserin 100 mg increased the number of satisfying sexual events by 0.5 to one additional event per month over placebo. [27] The result of the present meta-analysis is within the range mentioned by the FDA for premenopausal women. Postmenopausal women treated with flibanserin 100 mg showed a similar change in PGI-I score compared to those treated with placebo (MD −0.15, 95% CI [−0.44, 0.14], P = .32, I2 = 56% [moderate heterogeneity]) (Fig.

Before using flibanserin

The efficacy of 50 mg of flibanserin is far less in the same population. The drug has minimal efficacy in postmenopausal women and is not yet approved for treating HSDD in them. In addition, a mean of 1.71 eDiary sexual desire score was increased among the premenopausal women treated with flibanserin 100 mg; flibanserin at 50 mg daily doses was proven ineffective in this regard. Moreover, the FSFI desire domain score, which is extensively used as a measure of sexual desire in women, showed the superiority of flibanserin over placebo in both premenopausal (mean increase 0.30 for 100 mg and 0.25 for 50 mg) and postmenopausal women (0.25 for 100 mg). In premenopausal women, a higher number of subjects achieved improvements in the PGI-I score in the flibanserin 100 mg arm (OR 1.93, 95% CI [1.58, 2.36], P < .00001, I2 = 32% [mild heterogeneity]) (Fig. Forest plot highlighting the (A) Change from baseline in PGI-I score in postmenopausal women, Flibanserin 100 mg vs Placebo; (B) Proportions of premenopausal women with improvement in PGI-I score, Flibanserin 100 mg vs Placebo; (C) Proportions of premenopausal women with improvement in PGI-I score, Flibanserin 50 mg vs Placebo; (D) Proportions of premenopausal women responded positively at PBE, Flibanserin 100 mg vs Placebo; (E) Proportions of premenopausal women responded positively at PBE, Flibanserin 50 mg vs Placebo; (F) Proportions of postmenopausal women responded positively at PBE, Flibanserin 100 mg vs Placebo. The percentage of premenopausal women who responded positively (“yes”) when asked whether they had experienced a meaningful benefit from the study medication was higher in the flibanserin 100 mg arm (OR 1.76, 95% CI [1.34, 2.31], P < .0001, I2 = 59% [moderate heterogeneity]) (Fig. For the same outcome, flibanserin 100 mg was better than placebo in postmenopausal women (OR 1.54, 95% CI [1.24, 1.90], P < .0001, I2 = 0% [not important heterogeneity]) (Fig. The safety outcomes of flibanserin versus placebo are summarized in Table 3.

Overdose/Missed Dose

Sensitivity analysis performed by omitting each trial to search for the sources of heterogeneity of flibanserin 100 mg on SSE in premenopausal women showed that none of the trials could substantially influence the pooled effect. Forest plot highlighting the change from baseline in (A) SSE in premenopausal women, Flibanserin 100 mg vs Placebo; (B) SSE in premenopausal women, Flibanserin 50 mg vs Placebo; (C) SSE in postmenopausal women, Flibanserin 100 mg vs Placebo; (D) e-Diary sexual desire score in premenopausal women, Flibanserin 100 mg vs Placebo; (E) e-Diary sexual desire score in premenopausal women, Flibanserin 50 mg vs Placebo. 3.5.2. eDiary sexual desire score Flibanserin 100 mg outperformed placebo in improving sexual desire score measured using eDiary (MD 1.71, 95% CI [0.43, 2.98], P = .009, I2 = 0% [not important heterogeneity], moderate certainty of evidence) (Fig. Such benefit was not observed with flibanserin 50 mg over placebo (MD 0.67, 95% CI [−0.71, 2.05], P = .34, I2 = 0% [not important heterogeneity]) (Fig.

Other Interactions

Effect of flibanserin on secondary efficacy outcomes Compared to placebo, greater increments in FSFI desire domain scores were observed in premenopausal women with flibanserin 100 mg (MD 0.30, 95% CI [0.29, 0.31], P < .00001, I2 = 0% [not important heterogeneity]) (Fig. A similar benefit was observed with flibanserin 100 mg in postmenopausal women (MD 0.25, 95% CI [0.06, 0.44], P = .01, I2 = 0% [not important heterogeneity]) (Fig. Forest plot highlighting the change from baseline in (A) FSFI-d score in premenopausal women, Flibanserin 100 mg vs Placebo; (B) FSFI-d score in premenopausal women, Flibanserin 50 mg vs Placebo; (C) FSFI-d score in postmenopausal women, Flibanserin 100 mg vs Placebo; (D) FSFI total score in premenopausal women, Flibanserin 100 mg vs Placebo; (E) FSFI total score in premenopausal women, Flibanserin 50 mg vs Placebo; (F) FSFI total score in postmenopausal women, Flibanserin 100 mg vs Placebo. Flibanserin 100 mg was better than placebo in improving FSFI total scores in both premenopausal (MD 2.51, 95% CI [1.47, 3.55], P < .00001, I2 = 90% [high heterogeneity]) (Fig. 3D), and postmenopausal women (MD 1.42, 95% CI [0.56, 2.29], P = .001, I2 = 0% [not important heterogeneity]) (Fig. The number of study subjects experiencing any AEs was higher in the flibanserin 100 mg arm (RR 1.37, 95% CI [1.14, 1.65], P = .009, I2 = 93% [high heterogeneity], very low certainty of evidence), and flibanserin 50 mg arm (RR 1.18, 95% CI [1.03, 1.36], P = .02, I2 = 72% [moderate heterogeneity]) (Fig. More study subjects on flibanserin 100 mg experienced drug-related AEs (RR 2.33, 95% CI [1.96, 2.76], P < .00001, I2 = 0% [not important heterogeneity]) and AEs leading to study discontinuation (RR 2.08, 95% CI [1.39, 3.10], P = .0003, I2 = 50% [moderate heterogeneity]) than those on placebo. Serious AEs and severe AEs were comparable between flibanserin and placebo groups. Table 3 - The results of safety outcomes of flibanserin vs placebo in the meta-analysis. More subjects taking flibanserin 100 mg (RR 3.95, 95% CI [2.40, 6.51], P < .00001, I2 = 70% [moderate heterogeneity], low certainty of evidence) and flibanserin 50 mg (RR 2.39, 95% CI [1.61, 3.55], P < .0001, I2 = 0% [not important heterogeneity]) experienced dizziness than those who took a placebo.

  • Direct comparison trials between flibanserin and bremelanotide are lacking.
  • Choice of treatment depends on patient preference, risk profile, and cost.
  • Psychological and interpersonal factors are important contributors to HSDD.
  • Combining medication with sex therapy or counseling may improve outcomes.
  • Flibanserin does not increase libido in individuals without HSDD.
  • It is not approved or intended for use as a recreational or enhancement drug.
  • Off-label use, such as in postmenopausal women or men, is not supported by evidence.
  • Healthcare providers must complete an online knowledge assessment for REMS certification.
  • Certification must be renewed periodically according to the REMS program.

Compared to the placebo group, a similar number of subjects in the flibanserin 100 mg and flibanserin 50 mg groups experienced headache. Fatigue (RR 1.91, 95% CI [1.30, 2.81], P = .01, I2 = 53% [moderate heterogeneity], low certainty of evidence), nausea (RR 2.37, 95% CI [1.69, 3.33], P < .000001, I2 = 54% [moderate heterogeneity], moderate certainty of evidence), somnolence (RR 4.04, 95% CI [3.15, 5.18], P < .000001, I2 = 0% [not important heterogeneity], moderate certainty of evidence), and insomnia (RR 1.69, 95% CI [1.09, 2.62], P = .02, I2 = 0% [not important heterogeneity], moderate certainty of evidence) were more frequent in the flibanserin 100 mg group than in the placebo group.

Select a medication above to begin.

The percentage of premenopausal women who responded positively (“yes”) when asked whether they had experienced a meaningful benefit from the study medication was higher in the flibanserin 100 mg arm (OR 1.76, 95% CI [1.34, 2.31], P < .0001, I2 = 59% [moderate heterogeneity]) (Fig. For the same outcome, flibanserin 100 mg was better than placebo in postmenopausal women (OR 1.54, 95% CI [1.24, 1.90], P < .0001, I2 = 0% [not important heterogeneity]) (Fig. The safety outcomes of flibanserin versus placebo are summarized in Table 3. The number of study subjects experiencing any AEs was higher in the flibanserin 100 mg arm (RR 1.37, 95% CI [1.14, 1.65], P = .009, I2 = 93% [high heterogeneity], very low certainty of evidence), and flibanserin 50 mg arm (RR 1.18, 95% CI [1.03, 1.36], P = .02, I2 = 72% [moderate heterogeneity]) (Fig. More study subjects on flibanserin 100 mg experienced drug-related AEs (RR 2.33, 95% CI [1.96, 2.76], P < .00001, I2 = 0% [not important heterogeneity]) and AEs leading to study discontinuation (RR 2.08, 95% CI [1.39, 3.10], P = .0003, I2 = 50% [moderate heterogeneity]) than those on placebo.

Brand Names: US

Serious AEs and severe AEs were comparable between flibanserin and placebo groups. Table 3 - The results of safety outcomes of flibanserin vs placebo in the meta-analysis. More subjects taking flibanserin 100 mg (RR 3.95, 95% CI [2.40, 6.51], P < .00001, I2 = 70% [moderate heterogeneity], low certainty of evidence) and flibanserin 50 mg (RR 2.39, 95% CI [1.61, 3.55], P < .0001, I2 = 0% [not important heterogeneity]) experienced dizziness than those who took a placebo. Compared to the placebo group, a similar number of subjects in the flibanserin 100 mg and flibanserin 50 mg groups experienced headache. Fatigue (RR 1.91, 95% CI [1.30, 2.81], P = .01, I2 = 53% [moderate heterogeneity], low certainty of evidence), nausea (RR 2.37, 95% CI [1.69, 3.33], P < .000001, I2 = 54% [moderate heterogeneity], moderate certainty of evidence), somnolence (RR 4.04, 95% CI [3.15, 5.18], P < .000001, I2 = 0% [not important heterogeneity], moderate certainty of evidence), and insomnia (RR 1.69, 95% CI [1.09, 2.62], P = .02, I2 = 0% [not important heterogeneity], moderate certainty of evidence) were more frequent in the flibanserin 100 mg group than in the placebo group. Subjects in the flibanserin 50 mg group also exhibited a cenforce 200 tablets higher risk of somnolence than the placebo group (RR 2.08, 95% CI [1.30, 3.35], P = .002, I2 = 34% [mild heterogeneity]). The present meta-analysis incorporated the results of RCTs of flibanserin in HSDD that are available to date. It highlights the efficacy and adverse events of flibanserin compared to a placebo used to manage HSDD in pre-and postmenopausal women. Flibanserin is more effective than placebo in treating HSDD, although its use is associated with higher risks of AEs. US FDA approved flibanserin in August 2015 as the first medication to treat acquired, generalized HSDD in premenopausal women. [27] Flibanserin is a non-hormonal oral medicine that acts on the brain to increase sexual desire. The mechanism by which flibanserin improves sexual desire and related distress is not known; this may be attributed to its high affinity for 5-HT1A and 5-HT2A receptors, displaying agonist activity on 5-HT1A and antagonist on 5-HT2A, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters. Serotonin exerts an inhibitory influence on sexual activity by reducing dopamine release in the prefrontal cerebral cortex. Both dopamine and norepinephrine are essential components in the process of sexual excitation. Norepinephrine serves as a stimulant in sexual arousal, while dopamine contributes to the enhancement of desire. By modulating these monoamines in patients with HSDD, flibanserin improves sexual desire and arousal. In premenopausal women, flibanserin use was associated with 0.69 and 0.32 additional SSE per month at 100 and 50 mg daily doses; the number was 0.37 in postmenopausal women with flibanserin 100 mg.

IMPORTANT WARNING:

Subjects in the flibanserin 50 mg group also exhibited a cenforce 200 tablets higher risk of somnolence than the placebo group (RR 2.08, 95% CI [1.30, 3.35], P = .002, I2 = 34% [mild heterogeneity]). The present meta-analysis incorporated the results of RCTs of flibanserin in HSDD that are available to date. It highlights the efficacy and adverse events of flibanserin compared to a placebo used to manage HSDD in pre-and postmenopausal women. Flibanserin is more effective than placebo in treating HSDD, although its use is associated with higher risks of AEs. US FDA approved flibanserin in August 2015 as the first medication to treat acquired, generalized HSDD in premenopausal women.

Interactions with Food/Tobacco/Alcohol

[27] Flibanserin is a non-hormonal oral medicine that acts on the brain to increase sexual desire. The mechanism by which flibanserin improves sexual desire and related distress is not known; this may be attributed to its high affinity for 5-HT1A and 5-HT2A receptors, displaying agonist activity on 5-HT1A and antagonist on 5-HT2A, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters. Serotonin exerts an inhibitory influence on sexual activity by reducing dopamine release in the prefrontal cerebral cortex. Both dopamine and norepinephrine are essential components in the process of sexual excitation. Norepinephrine serves as a stimulant in sexual arousal, while dopamine contributes to the enhancement of desire. The improvement is not as robust as expected. US FDA report on the approval of flibanserin 100 mg mentioned that, on average, treatment with flibanserin 100 mg increased the number of satisfying sexual events by 0.5 to one additional event per month over placebo. [27] The result of the present meta-analysis is within the range mentioned by the FDA for premenopausal women. The efficacy of 50 mg of flibanserin is far less in the same population. The drug has minimal efficacy in postmenopausal women and is not yet approved for treating HSDD in them. In addition, a mean of 1.71 eDiary sexual desire score was increased among the premenopausal women treated with flibanserin 100 mg; flibanserin at 50 mg daily doses was proven ineffective in this regard. Moreover, the FSFI desire domain score, which is extensively used as a measure of sexual desire in women, showed the superiority of flibanserin over placebo in both premenopausal (mean increase 0.30 for 100 mg and 0.25 for 50 mg) and postmenopausal women (0.25 for 100 mg).